Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Napredovali MTC - izziv za zdravljenje
Authors:Bergant, Damijan (Author)
Tipology:1.04 - Professional Article
Organisation:Logo OI - Institute of Oncology
Year of publishing:2009
COBISS_ID:25707993 Link is opened in a new window
ISSN on article:1408-1741
OceCobissID:65324032 Link is opened in a new window
Files:.pdf PDF - Presentation file, download (136,71 KB)
Onkološki inštitut
Rights:by Authors
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


License:CC BY 4.0, Creative Commons Attribution 4.0 International
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Title:Advanced Medullary Thyroid Carcinoma – a Challenge for Multimodal Treatment (Case Presentation)
Abstract:Medullary thyroid cancer is a rare, neuroendocrine, tumor. It arises from parafollicular or C-cells with the ability to produce and secrete different bioactive substances like calcitonin (TC) and CEA. MTC occurs as a sporadic tumor or in hereditary settings MEN 2A, MEN 2B and FMCT. Germ line point mutations in RET proto-oncogene are responsible for tumor rise and inheritance of settings. RET mutations diagnostics in MTC patients and their first degree relatives form the basis of genetic screening. Biological behavior of MTC shows great clinical variability. Surgery is still the treatment of choice for MTC while teleradiotherapy, chemotherapy and radioimmunotherapy are indicated in advanced disease. Molecularly targeted treatments are now part of clinical studies with some promising results. Status at admission is still the most important prognostic factor. Diagnostics, treatment - including molecularly targeted treatment and follow-up of 29-years-old patient with respiratory distress due to the advanced MTC is represented. In this case, inhibitors of receptor tyrosine kinases were used for the first time as a part of multimodal treatment of MTC at the Institute of Oncology (OI).